Generic Medicine Info
Indications and Dosage
Hyperactivity disorders
Child: Initially 37.5 mg daily in the morning, increase at wkly intervals by 18.75 mg. Usual dose: 56.25-75 mg/day; max dose: 112.5 mg/day.
Liver impairment; children <6 yr; Tourette's syndrome; psychosis.
Special Precautions
Should only be started in patients with normal baseline LFTs; monitor LFTs every 2 wk. Discontinue if serum alanine aminotransferase is increased, if signs of liver failure develop or if no substantial clinical response within 3 wk of completing dose titration. Renal dysfunction, psychosis, bipolar disorder, DM, cardiovascular disease, seizure disorders, insomnia, porphyria, or hypertension. Potential for drug dependency. Avoid abrupt withdrawal in chronic patients. May impair ability to drive or operate machinery. Pregnancy and lactation.
Adverse Reactions
Insomnia, night terrors, nervousness, restlessness, irritability, euphoria, fatigue and depression; dryness of the mouth, anorexia, abdominal cramps and other GI disturbances; headache, dizziness, tremor, sweating, tachycardia, palpitations, MI, hypertension or hypotension, altered libido, and impotence. Possible growth suppression in children.
Potentially Fatal: Hepatotoxicity.
Anorexia, choreoathetosis, dyskinesias, elevated LFTs, exacerbation of Tourette's syndrome, hallucinations, hyperthermia, insomnia, leukocytosis, mania, mydriasis, neutropenia, nystagmus, rhabdomyolysis, stuttering, vomiting.
Drug Interactions
Hypertensive crisis with MAOIs. Reduced seizure threshold in epileptic patients on antiepileptics.
Lab Interference
Interferes with tests for prostatic acid phosphatase used in prostatic carcinoma diagnosis; produces false acid phosphatase elevations.
Mechanism of Action: Pemoline is a CNS stimulant. It is an indirect-acting sympathomimetic with alpha- and beta-adrenergic agonist activity.
Onset: Peak effect: 4 hr
Duration: 8 hr
Absorption: Readily absorbed from the GI tract.
Distribution: Approx 50% bound to plasma proteins.
Metabolism: Hepatic.
Excretion: Via urine, faeces (negligible amounts). Half-life elimination: Children: 7-8.6 hr; adults: 12 hr.
MIMS Class
Other CNS Drugs & Agents for ADHD
Disclaimer: This information is independently developed by MIMS based on Pemoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in